Références

Information sur le cancer / Types de cancer / Peau - Mélanome / Traitement / Traitement ciblé

Alberta Health Services. (2015, August). Systemic Therapy for Unresectable Stage III or Metastatic Cutaneous Melanoma Clinical Practice Guideline CU-012 (version 3). Extrait de: http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-cu012-systemic-therapy.pdf.

American Society of Clinical Oncology. (2015, September). Melanoma. Extrait de: http://www.cancer.net/cancer-types/melanoma/view-all.

Cancer Care Ontario. (2016, April). Drug Monograph: Dabrafenib. Extrait de: https://www.cancercare.on.ca/toolbox/drugformulary/.

Cancer Care Ontario. (2016, April). Drug Monograph: Cobimetinib. Extrait de: https://www.cancercare.on.ca/toolbox/drugformulary/.

Cancer Care Ontario. (2016, June). Drug Monograph: Imatinib. Extrait de: https://www.cancercare.on.ca/toolbox/drugformulary/.

Cancer Care Ontario. (2016, January). Drug Monograph: Vemurafenib. Extrait de: https://www.cancercare.on.ca/toolbox/drugformulary/.

Health Canada, Drugs and Health Products. (2016, March 30). Summary Basis of Decision (SBD): Cotellic. Extrait de: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2016-cotellic-182788-eng.php#sbd.

National Comprehensive Cancer Network. (2016). NCCN Clinical Practice Guidelines in Oncology: Melanoma (Version 2.2016).

National Institutes of Health. (2016, June). Genetics Home Reference: BRAF. Bethesda, MD: US National Library of Medicine. Extrait de: https://ghr.nlm.nih.gov/gene/BRAF.

Princess Margaret Cancer Centre. (2015, August). Princess Margaret Cancer Centre Clinical Practice Guidelines: Melanoma. Extrait de: http://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Melanoma_Skin_Oncology/Pages/clinical_practice_guidelines.aspx.

×
×